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Abstract
Background: Stanniocalcin-1(STC-1) is up-regulated in several cancers including gastric cancer. Evidences suggest
that STC-1 is associated with carcinogenesis and angiogenic process. However, it is unclear on the exact role for
STC-1 in inducing angiogenesis and tumorigeneisis.
Method: BGC/STC cells (high-expression of STC-1) and BGC/shSTC cells (low- expression of STC-1) were
constructed to investigate the effect of STC-1 on the xenograft tumor growth and angiogenesis in vitro and in vivo.
ELISA assay was used to detect the expression of vascular endothelial growth factor (VEGF) in the supernatants.
Neutralizing antibody was used to inhibit VEGF expression in supernatants. The expression of phosphorylated
-PKCbII, phosphorylated -ERK1/2 and phosphorylated -P38 in the BGC treated with STC-1protein was detected by
western blot.
Results: STC-1 could promote angiogenesis in vitro and in vivo, and the angiogenesis was consistent with VEGF
expression in vitro. Inhibition of VEGF expression in supernatants with neutralizing antibody markedly abolished
angiogenesis induced by STC-1 in vitro. The process of STC-1-regulated VEGF expression was mediated via PKCbII
and ERK1/2.
Conclusions: STC-1 promotes the expression of VEGF depended on the activation of PKCbII and ERK1/2 pathways.
VEGF subsequently enhances tumor angiogenesis which in turn promotes the gastric tumor growth.
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Background
Development of gastric cancer involves multiple factor
changes that lead to the transformation of human
gastric epithelial cells to gastric cancer cells [1]. Angio-
genesis is a critical hallmark of malignancy and can
occur at different stages of the tumor progression [2].
Acquisition of the angiogenic phenotype can result from
genetic changes or local environmental changes such as
the secretion of pro-angiogenic growth factors by tumor
that lead to the activation of endothelial cells. Stannio-
calcin-1(STC-1) is a glycoprotein hormone originally
discovered in the corpuscles of Stannius of bony fish
[3]. The expression of the mammalian STC-1 was found
in numerous developmental and pathophysiological
processes [4-8]. Growing evidence suggests that the
mammalian STC-1 may be associated with carcinogen-
esis. Aberrant STC-1 expression has been reported in
breast and ovarian cancers [9-11]. Our previous study
found that STC-1 gene could be activated in human
gastric cancer BGC823 cells with over-expressed mid-
kine [12]. Midkine is a heparin-binding growth factor,
which was highly expressed in various malignant tumors
and the increased expression of midkine was signifi-
cantly associated with the advanced clinical stage and
distant metastasis of gastric cancer [13].
Recent works indicated that STC-1 may be involved
in the control of the angiogenic process [14]. In colon
cancers, STC-1 was highly expressed during angiogenesis
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primarily by the tumor vasculature [15]. VEGF is an
important angiogenetic factor and stimulates the prolifera-
tion and migration of endothelial cells [16]. Many studies
have verified that the expression of STC-1 is related with
VEGF [17,18]. Moreover, several reports have shown that
PKC plays an important role in regulating VEGF expres-
sion in angiogenesis process [19,20]. ERK [21-23], STAT3
[24], P38 and JNK [25] signaling pathway are also involved
in the positive control of VEGF expression. However, the
exact role for STC-1 in inducing both tumorigeneisis and
angiogenesis in cancer is not well understood.
In our present study, we found that STC-1 can pro-
moted angiogenesis in vivo and in vitro.M o r e o v e r ,w e
validated that VEGF is a key angiogenesis factor in
STC-1 induced angiogenesis. Furthermore, PKCbII and
ERK1/2 signaling pathway mediated STC-1-regulated
VEGF expression. We conclude that STC-1 can increase
VEGF expression to promote angiogenesis depended on
PKCbII and ERK1/2 signaling pathway.
Results
STC-1 promotes tumor proliferation and
angiogenesis in vivo
We successfully constructed BGC/STC cell and BGC/
shSTC cell line. SiRNA#2, the most effective inhibitor,
was used to construct Psilencer4.1™/STC-1 plasmids
(Additional file 1 Figure S1A). STC-1 cDNA obtained
from gastric tissues were used to construct pcDNA3.1/
STC-1 plasmids. STC-1 expressions in BGC823 and
transfected BGC823 cells (BGC/CON cell, BGC/STC
cell, BGC/shCON cell and BGC/shSTC cell) were con-
firmed in both mRNA and protein (Additional file 1,
Figure S1B, Figure S1A) level. All these cells were cul-
tured under standard culture conditions for 24 h, and
found to exhibit the same morphology (Additional file 1,
Figure S1C). Afterward, we analyze the tumorigenicity of
these stable transfectant in vivo. BGC823 cells and
transfected BGC823 cells were injected into the flank of
nude mice, and these mice were named as BGC mice,
BGC/CON mice, BGC/STC mice, BGC/shCON mice
and BGC/shSTC mice. Tumor volumes were measured
and calculated. The results showed that the tumor
volumes were significantly larger in BGC/STC mice and
extremely smaller in BGC/shSTC mice compared with
those in BGC mice (Figure 1B). And STC-1 protein
expression level was stronger in BGC/STC mice and
lower in BGC/shSTC mice (Figure 1C).
We then investigated whether the proliferation of tumor
cells was associated with STC-1 expression in vivo.T h e
density of PCNA, a proliferation marker of tumor cells,
was evidently higher in tumor tissues from BGC/STC
mice and lower in tumor tissues from BGC/shSTC mice
than that from BGC mice, BGC/CON mice or BGC/
shCON mice (Figure 1D, E). However, the proliferation
and cell apoptosis of BGC cell, BGC/CON cell, BGC/
STC cell, BGC/shCON cell and BGC/shSTC cell had no
significant change in vitro (Additional file 1, Figure S1D,
S1E). The in vivo and in vitro experiments suggest that
STC-1 may promote tumorgenesis through other
mechanism, other than tumor cell proliferation itself.
It has been known that angiogenesis have an important
role in tumor growth. So we checked the angiogenesis in
vivo. The results showed that the vascularity was increased
in BGC/STC mice and reduced in BGC/shSTC mice com-
pared to BGC mice or BGC/CON mice (Figure 1F, G).
This indicated that STC-1 may promote the tumor growth
in vivo depended on tumor angiogenesis.
Effects of STC-1 on HUVEC proliferation, migration
and tube formation in vitro
To determine the effect of STC-1 on angiogenesis, we
use CFSE staining to detect proliferation rate of
HUVECs. We found that BGC/STC culture superna-
tants could significantly promote HUVEC proliferation,
while BGC/shSTC culture supernatants could inhibit
HUVEC proliferation (Figure 2A). Then we considered
whether the culture supernatants could regulate the
migration of HUVEC. The Millicell cell culture insert
was used to study the migration of the HUVEC in vitro.
The migration of HUVEC was significantly enhanced
with BGC/STC medium cultured, while the migration
was reduced with BGC/shSTC medium cultured (Figure
2B, D). Tube formation assay was further verified the
effect of STC-1 on this angiogenesis process. The for-
mation of tube or cordlike structure could be induced
by all kinds of tumor cell supernatants cultured with
HUVEC, but not 1640 medium. Notably, BGC/STC
supernatants showed an augmentation effect on the
tube network while BGC/shSTC supernatants resulted
in shorter and more blunted tubes (Figure 3A, C).
These results suggest that STC-1 may change some
factors of tumor microenvironment to modulate
angiogenesis.
VEGF is neceseary to STC-1 promoting angiogenesis
It is well known that VEGF is one of the most common
promoters of angiogenesis, as an angiogenetic factor
[16], so we investigated whether STC-1 could regulate
the expression of VEGF in the gastric cancer cell. We
found that ectopic-expression of STC-1 could promote
VEGF production in the gastric cancer cell (Figure4A).
Moreover, the same result can be obtained when STC-1
protein was added to culture media (Figure4E). How-
ever, when VEGF neutralizing antibody was used to
neutralize VEGF in the culture supernatants of HUVEC
He et al. Journal of Biomedical Science 2011, 18:39
http://www.jbiomedsci.com/content/18/1/39
Page 2 of 9cells, the tube formation (Figure2C, D) and cell migra-
tion(Figure3B, C) of the cell induced by STC-1 were
markedly abolished in vitro. This means that VEGF
indeed promoted the process of angiogenesis. Isotype
antibody was used to further confirm that VEGF play an
important role in the process of STC-1 regulated
angiogenesis (Figure 2E, 3D).
STC-1 promotes VEGF expression primarily through
PKCbIIand ERK1/2 signaling pathway
To understand the regulation of VEGF expression by
STC-1, we investigated the main signaling pathways
r e l a t e dt oV E G Fe x p r e s s i o n .W ef o u n dt h a tS T C - 1
could activate both PKCbII and ERK1/2 pathways in
time- ang concentration-dependent patterns (Figure4B,
Figure 1 Tumorigenesis and angiogenesis of BGC cells in nude mice. (A) Western blotting analysis of the expression of STC-1 in BGC after
stable transfection. (B) Mean volumes of the tumor in each group were calculated. Cultured BGC cells and BGC stable transfection cells (10
6
cells) were injected subcutaneously into the flank of female nude mice. Tumor volumes were measured and calculated once every two days
after we can see the tumor in the flank of nude mice. (C) Immunohistochemical staining of STC-1 in tumor tissues of nude mice. STC-1 was
detected on the membrane of tumor cells (D) Immunohistochemical staining of PCNA in tumor tissues of nude mice. PCNA was detected in the
nucleus of tumor cells. (E) Quantification of PCNA expression(the Integrated Optical Density (IOD) of PCNA) by image pro-plus software. All
histology was carried out on multiple sections from individual mice and three independent in vivo experiments. (F) Hematoxylin and eosin
stained sections of the Matrigel plugs (E, endothelial-like cells; T, tumor cells; S, surrounding tissues; V, microvessels). (G) Mean vessel area was
quantified in each group. (*P < 0.05, **P < 0.01).
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CGP53353 and PD98059 respectively, to check which
pathway related to VEGF expression enhanced by
STC-1, and found that VEGF expression can be strongly
inhibited by one or both of these inhibitors was used
(Figure 4E, F).
Discussion
Many studies previously have uncovered the biological
f u n c t i o n so fS T C - 1i nm a m m a l s[ 3 , 4 ] .I ti sf o u n dt ob e
highly expressed in many cancers, such as gastric can-
cer, colon cancer, ovarian cancer and breast cancer
[9-11,26,27]. These observations suggest that STC-1
might play an important role in cancer development. In
this study, we for the first time showed that STC-1
enhances the expression of VEGF in gastric cancer cells
and promotes tumor growth through enhancing tumor
angiogenesis.
The effect of STC-1 on cell proliferation is still contro-
versial. Wu et al. found a direct inhibitory effect of STC-
1 on mammalian longitudinal bone growth [28] while
Liang et al reported that down-regulation of STC-1
enhanced the proliferation of breast cancer cell lines.
However, a recent study showed that over-expression of
STC-1 in ovarian cancer cells enhanced cell proliferation,
migration, and tube formation in vitro and increased the
growth of xenograft tumors in mice [29]. In this study,
we found that STC-1 had no effect on BGC cell prolifera-
tion in vitro. However, it significantly promoted tumor
growth in vivo. This suggests thatSTC1-induced tumori-
genesis is not through enhancing cell proliferation
directly. There might be other mechanisms that promote
tumorigenesis. It is well known that the development of
tumors is dependent upon neovascularization [30,31].
Previous studies have proved that STC-1 is highly
expressed in tumor vasculature in breast adenocarcino-
mas and colon cancers [26,32]. A recent study by G.
Basini et al. reported that STC-1 might be involved in the
angiogenic process [33]. Therefore, we speculated that
STC-1 might regulate the tumor development through
enhancing tumor angiogenesis. This hypothesis was con-
firmed by in vivo and in vitro angiogenesis experiments.
Based on these results, we proposed the below model
for STC-1-mediated oncogenesis. STC-1 has no direct
Figure 2 Effects of STC-1 and VEGF on HUVEC cell proliferation, tube formation. (A) CFSE positive cells were gated and CFSE fluorescence
intensity was showed in histograms. HUVEC were seeded in 12-well plates in triplicate and incubated with different culture supernatants. After
72 h, HUVEC proliferation was detected by FACS. (B) Tube formation of HUVEC induced by different culture supernatants was photographed
under a microscope at ×100 magnification. (C) Effects of VEGF on tube formation of HUVEC. Tube formation of HUVECs was photographed
under a microscope at ×100 magnification. (D) Mean tube length was quantified by image pro-plus software. All histogram was carried out on
multiple sections and the results are representative of three independent experiments. (E) effect of isotype antibody on cell migration. IS: isotype
antibody; V:VEGF neutralizing antibody; BGC/STC+IS: BGC/STC cell supernatants added with isotype antibody; BGC/STC+V: BGC/STC cell
supernatants added with VEGF neutralizing antibody.
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tumor angiogenesis which in turn changes tumor
microenvironments. The altered microenvironment
induces the sprouting of new blood vessels from the
established vasculature, resulting in a tumor vascular
system. This tumor vascular system enables tumor cells
to obtain enough oxygen and nutrients for survival and
proliferation.
It is well recognized that VEGF is regulated by many
pathways such as phosphorylated PKCbII, phosphory-
lated P38, and phosphorylated ERK1/2 [19,21,25]. We
found STC-1 could activate PKCbIIand ERK1/2 proteins
rather than P38. Blocking PKCbII or ERK1/2 reversed
the expression of VEGF induced by STC-1, indicating
that STC-1 regulates VEGF expression through PKCbII
or ERK1/2 pathways. Moreover, we found that a combi-
nation of PKC and ERK1/2 inhibitors has the similar
effect as PKCbII inhibitor itself (Figure4E). This may
indicate that the ERK signaling pathway is a potential
PKCbII target, which is agreement with other studies
[34]. However, previous studies have proved that VEGF
could regulate STC-1 expression. This may indicate that
there may be a positive feedback regulation between
STC-1 and VEGF.
Conclusions
Our study showed that STC-1 promotes the expression
of VEGF depended on the activation of PKCbII and
ERK1/2 pathways. VEGF subsequently enhances tumor
angiogenesis which in turn promotes the gastric tumor
growth.
Materials and methods
Material
PD98059 (selective inhibitor of ERK signaling pathway)
and CGP53353 (selective inhibitor of PKCbII signaling
pathway) were obtained from TOCRIS Bioscience Com-
pany (Bristol, UK) and Beyotime Institute of Biotechnol-
ogy (Haimen, China), respectively. Stanniocalcin-1
monoclonal human antibody was obtained from R&D
Company. VEGF Rabbit Monoclonal Antibody (Bioac-
tive), which can block ligand-receptor interaction, was
obtained from Epitomics Company. Cell Apoptosis kit
was obtained from MBL International Corporation
(Watertown, MA). The recombinant human stanniocal-
cin-1 protein was obtained from PROSPEC (Protein
Specialists) Company. Celltrace™ CFSE cell Prolifera-
tion kit (C34554) was obtained from Invitrogen
Company.
Figure 3 Effects of STC-1 and VEGF on HUVEC cell migration. (A) Effects of STC-1 on HUVEC migration. HUVEC were seeded in triplicate on
inserts, and incubated for 12 h with different conditioned supernatants. (B) Effects of VEGF on HUVEC migration. HUVEC were seeded in
triplicate on inserts, and incubated for 12 h with tumor supernatants incubated with 2 μg/mL VEGF monoclonal antibody (Bioactive). (C) The
number of migration cells was quantified under a microscope at ×100 magnification. All histogram was carried out on multiple sections and the
results are representative of three independent experiments. (D) Effect of isotype antibody on cell migration. IS: isotype antibody; V:VEGF
neutralizing antibody; BGC/STC+IS: BGC/STC cell supernatants added with isotype antibody; BGC/STC+V: BGC/STC cell supernatants added with
VEGF neutralizing antibody.
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Human gastric adenocarcinoma cell line BGC823 and
Human umbilical vein endothelial cells (HUVECs)
were obtained from Shanghai Institute of Cell Biology
(Shanghai, China). BGC823 cells were cultured in
RPMI1640 medium (Gibco, USA) supplemented with
10% fetal bovine serum (FBS) (Gibco, USA), 10 mg/ml
streptomycin and 10,000 units/ml penicillin. G418
sulate (Merck, German) was additionally added in
BGC/STC (STC-1 high expression) and BGC/shSTC
cells (STC-1 low expression. HUVECs were grown in
RPMI1640 medium supplemented with 10% FBS. Cells
were incubated in a humidified atmosphere of 5% CO2
at 37°C.
Plasmids construction and transfection
STC-1 cDNA, acquired from human gastric carcinoma
tissues, was purified, digested, and ligated to pcDNA3.1
vector. Three siRNAs fragments targeted STC-1 were
designed by online software http://rnaidesigner.invitro-
gen.com/rnaiexpress/. The most effective siRNA frag-
ment was converted to shRNA and then was inserted
into pSiencer4.1. PcDNA3.1/STC-1 and pSilencer4.1/
STC-1-shRNA plasmids were constructed and trans-
fected into BGC823 cells with Lipofectamine 2000
reagent according to the manufacturer’s instructions.
Tumor culture supernatants collection
BGC cell, BGC/CON cell, BGC/STC cell, BGC/shCON
cell, and BGC/shSTC cell were seeded at 5 × 10
5 cells/
well in triplicate on 6 well plates with 10% FBS-1640
medium, refreshed medium with serum-free 1640 med-
ium. After 24 h, the culture supernatants were collected,
centrifuged at 4°C, 4000 rcf for 10 min, and stored at
-70°C for subsequent use. Tumor supernatants were
labeled as BGC supernatant, BGC/CON supernatant,
BGC/STC supernatant, BGC/shCON supernatant, and
BGC/ shSTC supernatant.
Figure 4 STC-1 promoted VEGF expressing through PKCbII signaling pathway. (A) VEGF expression in the different culture supernatants.
ELISA assay was used to detect VEGF expression in the culture supernatants. (B) Time courses of PKCbIIand ERK1/2 avtivation induced by STC-1.
BGC823 were treated with 50 ng/mL STC-1 for 15, 30, 45, 60 min. Whole- cell lysates were prepared and immunoblotted with antibodies to
phosphor-PKC bII, total PKC bII, phosho-ERK1/2 and total ERK1/2. (C) Concentration courses of PKC bIIand P38 activation induced by STC-1. BGC823
were treated with different concentrations STC-1 for 45 min. Whole- cell lysates were prepared and immunoblotted with antibodies to phosphor-
PKC bII, total PKC bII, phosho-P38 and total P38. The results are representative of three independent experiments. (D) Concentration courses of
ERK1/2 activation induced by STC-1. BGC823 were treated with different concentrations STC-1 for 45 min. Whole- cell lysates were prepared and
immunoblotted with antibodies to phosho-ERK1/2 and total ERK1/2. The results are representative of three independent experiments. (E) Effect of
STC-1 on VEGF is mediated through PKCbII and ERK1/2 signaling. BGC823 was exposed to either CGP53353 (0.5 μM) or PD98059 (25 μM) for three
hours and then individually with STC-1 for 24 h. The results are representative of three independent experiments. VEGF expression in BGC823 cell
culture supernatants was determined by ELISA. (F) CGP53353 and PD98059 could inhibit PKC bIIand ERK activation, respectively.
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Cells were labeled with 5-(and -6) carboxyfluorescein dia-
cetate succinimidyl ester (CFSE; Molecular Probes, Invi-
trogen, USA) according to the manufacturer’sp r o t o c o l .
A 5 mM stock solution of CFSE was prepared by dissol-
ving in DMSO and stored at -20°C. Before labeling, cells
were washed and re-suspended in PBS containing 0.1%
BSA (PBS/BSA). CFSE was then added into the cell sus-
pensions at a final concentration of 5 μM, and incubated
for 15 min at 37°C. The cells were subsequently washed
with complete RPMI 1640 medium and re-suspended in
complete RPMI 1640 medium for culture. After incuba-
tion for days 3, the cells were harvested for the division
analysis of CFSE-labeled cells by FACS.
Xenografts experiments
Female BALB/c nude mice (5-6 weeks old) were
obtained from Military Medical Sciences Laboratory
Animal Research Center (Beijing, China). 10
6cell/100 μL
PBS were injected subcutaneously into the flank of
female nude mice (n = 6). Tumor volumes were mea-
sured once every two days when tumors can be
observed and calculated by the formula: Volume =
(width)
2× length/2.
Immunohistochemistry analysis
Tumor tissues were harvested, fixed in 10% buffered for-
malin, dehydrated, bisected, mounted in paraffin, and
sectioned for immunohistochemistry (IHC). Hydrated
sections were stained using Hematoxylin/Eosin. IHC
was carried out with antibodies specific for PCNA (Pro-
liferating Cell Nuclear Antigen) using rabbit anti-mouse
PCNA (1:1600, Dako Cytomation, Denmark) or Mono-
clonal Anti-human Stanniocalcin-1 antibody (R&D Sys-
tems, Inc.). The quantitation of PCNA density was
normalized to the Integrated Optical Density (IOD) of
PCNA via Image Pro Plus software. All histology was
carried out on multiple sections from individual mice
and three independent in vivo experiments.
HUVEC migration assay
The assay was performed using cell culture inserts (8
μm pore size) (Millipore Cell, US). 2 × 10
4 HUVEC
cells/well were seeded onto inserts with serum-free
RPMI 1640 medium in triplicate. Then they were put
into a 24-well culture plate containing 500 μlt u m o r
supernatants. 12 h later, the inserts were removed and
washed with PBS, fixed, stained, rinsed with water, and
photographed in 3 random fields (400×, or 200×) per
insert under upright microscope.
HUVEC tube formation assay
6×1 0
4 HUVEC cells were seeded in triplicate on Matri-
gel coated 24-well plates in 500 μl RPMI 1640 with 10%
FBS, cultured at 37°C. Cell culture medium was then
replaced by 500 μl tumor supernatants. After 12 h, tube
formations were observed under upright microscope.
Tube-like structures were defined as endothelial cord
formations that were connected at both ends and the
mean tube length in five random fields per well was
quantified.
In vivo angiogenesis assay
Matrigel were carefully mixed with tumor cells and
64U/ml heparin. Matrigel mixtures (0.1 ml, 5 × 10
5
cells) were injected subcutaneously into the armpit
region of 6-week-old female BALB/c nude mice. At day
14, Matrigel plugs were removed and sectioned for
Hematoxylin/Eosin, the vascularity was calculated in five
random fields per section by OlyVIA software and
Image-Pro Plus software.
Western Blot
Western blot analysis was performed using antibodies
against anti-PKCbII and anti-PKCbII Phospho rabbit
monoclonal antibody (Epitomics, CA, USA) diluted at 1:
1000, the monoclonal antibody anti- ERK1/2 and
anti-ERK1/2 Phospho, anti- P38 and anti-P38 Phospho
(Cell Signaling Technology, USA) at 1: 1000, and the
anti-btubulin rat monoclonal antibody (Beyotime,
China) at 1:1000.
VEGF Assay
VEGF content in tumor culture supernatants was
quantified by an enzyme-linked immunosorbent assay
(ELISA) kits (DAKEWE Company, China) according to
the manufacturer’s instructions. All assays were
duplicated.
Statistical Analysis
All results are presented as means ± S.E.M of at least
three independent experiments, unless otherwise indi-
cated. Student’s t test was employed to assess differences
between two groups. A value of p < 0.05 was considered
to be statistically significant.
Additional material
Additional File 1: Construction of plasmids and verification of
transfected BGC cells. (A) Cells were transiently transfected with STC-1
siRNA#1, STC-1 siRNA#2, STC-1 siRNA#3 for 24 h. Whole-cell lysates were
analyzed for the levels of STC-1 by RT-PCR. (B) the expression of STC-1 in
BGC823 after transfection was confirmed by RT-PCR analysis. (C) Cellular
phenotypes after stable transfection. (D) Proliferation of all BGC and
transfected BGC cells (5 × 10
4 cells/well) were determined by FACS, CFSE
positive cells were gated and CFSE fluorescence intensity was showed in
histograms. (E) Cell apoptosis of all BGC and transfected BGC cells.
Apoptotic cells were stained using the Annexin V-FITC Apoptosis
Detection Kit following the manufacturer’s instruction.
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ERK1/2: extracellular signal-regulated protein kinase ½; HUVEC: Human
umbilical vein endothelial cell; PCNA: Proliferating Cell Nuclear Antigen;
PKCβII: intracellular protein kinaseβII; STC-1: Stanniocalcin-1; VEGF: Vascular
endothelial growth factor.
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